5.59
-0.33(-5.57%)
Currency In USD
Address
85 Wells Avenue
Newton, MA 02459
United States of America
Phone
617 658 0600
Website
Sector
Healthcare
Industry
Biotechnology
Employees
279
First IPO Date
November 06, 2013
| Name | Title | Pay | Year Born |
| Mr. Richard A. Paulson M.B.A. | President, Chief Executive Officer & Director | 1.21M | 1967 |
| Dr. Mansoor Raza Mirza M.D. | Clinical Consultant, Member of Scientific Advisory Board & Independent Director | 150,000 | 1961 |
| Mr. Michael J. Mano J.D. | Senior Vice President, General Counsel & Secretary | 625,075 | 1978 |
| Ms. Sohanya Cheng M.B.A. | Executive Vice President, Chief Commercial Officer & Head of Business Development | 779,035 | 1983 |
| Dr. Reshma Rangwala M.D., Ph.D. | Executive Vice President, Chief Medical Officer & Head of Research | 808,650 | 1978 |
| Dr. Sharon Shacham M.B.A., Ph.D. | Co-Founder & Chairman of Scientific Advisory Board | 1.4M | 1970 |
| Ms. Kristin Abate | Vice President, Chief Accounting Officer & Assistant Treasurer | 0 | N/A |
| Mr. James Accumanno J.D. | Chief Compliance Officer | 0 | N/A |
| Ms. Lori A. Macomber CPA | EVice President, Chief Financial Officer & Treasurer | 0 | 1972 |
| Mr. Brendan Twohig Strong | SVice President of Investor Relations & Corporate Communications | 0 | N/A |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.